Evolus (EOLS) Stock Forecast, Price Target & Predictions
EOLS Stock Forecast
Evolus stock forecast is as follows: an average price target of $24.00 (represents a 46.16% upside from EOLS’s last price of $16.42) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
EOLS Price Target
The average price target for Evolus (EOLS) is $24.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $27.00 to $20.00. This represents a potential 46.16% upside from EOLS's last price of $16.42.
EOLS Analyst Ratings
According to 4 Wall Street analysts, Evolus's rating consensus is 'Buy'. The analyst rating breakdown for EOLS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Evolus Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 03, 2024 | Douglas Tsao | H.C. Wainwright | $27.00 | $17.05 | 58.40% | 64.43% |
| Sep 13, 2024 | Balaji Prasad | Barclays | $20.00 | $16.46 | 21.51% | 21.80% |
| Sep 13, 2024 | Vamil Divan | Mizuho Securities | $25.00 | $16.46 | 51.88% | 52.25% |
| Jan 29, 2024 | Balaji Prasad | Barclays | $16.00 | $13.47 | 18.78% | -2.56% |
The latest Evolus stock forecast, released on Oct 03, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $27.00, which represents a 58.40% increase from the stock price at the time of the forecast ($17.05), and a 64.43% increase from EOLS last price ($16.42).
Evolus Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 4 |
| Avg Price Target | - | $24.00 | $22.00 |
| Last Closing Price | $16.42 | $16.42 | $16.42 |
| Upside/Downside | -100.00% | 46.16% | 33.98% |
In the current month, the average price target of Evolus stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Evolus's last price of $16.42. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 13, 2024 | Needham | Buy | Buy | Hold |
| Sep 13, 2024 | Barclays | Overweight | Overweight | Hold |
| Jan 29, 2024 | Barclays | - | Overweight | Upgrade |
| Jan 17, 2024 | Needham | Buy | Buy | Hold |
| Jan 17, 2024 | Cantor Fitzgerald | Buy | Buy | Hold |
| Jun 24, 2022 | Needham | - | Buy | Initialise |
Evolus's last stock rating was published by H.C. Wainwright on Oct 03, 2024. The company gave EOLS a "Buy" rating, the same as its previous rate.
Evolus Financial Forecast
Evolus Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $59.33M | $49.32M | $48.68M | $41.72M | $43.65M | $33.90M | $37.16M | $33.91M | $34.66M | $26.68M | $26.10M | $12.24M | $20.58M | $17.66M | $7.81M | $10.50M | $19.45M | $13.17M | $2.31M |
| Avg Forecast | $108.10M | $86.30M | $84.00M | $77.30M | $77.26M | $63.17M | $64.93M | $57.27M | $60.19M | $44.35M | $49.30M | $40.57M | $43.89M | $36.00M | $36.60M | $29.83M | $34.76M | $25.41M | $24.67M | $11.11M | $21.20M | $11.51M | $1.93M | $15.24M | $18.02M | $3.97M | $341.17K |
| High Forecast | $108.10M | $86.30M | $84.00M | $77.30M | $77.26M | $64.75M | $64.93M | $57.27M | $60.33M | $44.35M | $49.30M | $40.57M | $43.89M | $36.00M | $36.60M | $29.83M | $34.76M | $25.41M | $24.67M | $11.11M | $21.20M | $11.51M | $1.93M | $15.24M | $18.02M | $3.97M | $341.17K |
| Low Forecast | $108.10M | $86.30M | $84.00M | $77.30M | $77.26M | $62.10M | $64.93M | $57.27M | $60.05M | $44.35M | $49.30M | $40.57M | $43.89M | $36.00M | $36.60M | $29.83M | $34.76M | $25.41M | $24.67M | $11.11M | $21.20M | $11.51M | $1.93M | $15.24M | $18.02M | $3.97M | $341.17K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | 0.99% | 1.11% | 0.99% | 1.03% | 0.99% | 0.94% | 1.02% | 1.14% | 1.00% | 1.05% | 1.06% | 1.10% | 0.97% | 1.53% | 4.04% | 0.69% | 1.08% | 3.32% | 6.77% |
Evolus's average Quarter revenue forecast for Mar 24 based on 4 analysts is $57.27M, with a low forecast of $57.27M, and a high forecast of $57.27M. EOLS's average Quarter revenue forecast represents a -3.48% decrease compared to the company's last Quarter revenue of $59.33M (Dec 23).
Evolus EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | $-25.21M | $-19.37M | $-20.05M | $-10.57M | $-9.45M | $-16.80M | $-18.52M | $-14.35M | $-2.49M | $-18.02M | $-13.38M | $9.24M | $-105.98M | $-6.82M | $-16.84M | $-15.10M | $-10.53M | $-23.30M | $-34.10M |
| Avg Forecast | $-69.07M | $-55.14M | $-53.67M | $-49.39M | $-49.37M | $-40.37M | $-41.49M | $-22.98M | $-38.46M | $-28.34M | $-31.50M | $-20.89M | $-15.71M | $-23.01M | $-23.39M | $-18.99M | $-22.21M | $-16.24M | $-15.76M | $-7.10M | $-13.55M | $-7.36M | $-1.23M | $-11.01M | $-11.52M | $-2.54M | $-218.00K |
| High Forecast | $-69.07M | $-55.14M | $-53.67M | $-49.39M | $-49.37M | $-39.68M | $-41.49M | $-18.39M | $-38.37M | $-28.34M | $-31.50M | $-16.71M | $-12.57M | $-23.01M | $-23.39M | $-15.19M | $-22.21M | $-16.24M | $-15.76M | $-7.10M | $-13.55M | $-7.36M | $-1.23M | $-8.81M | $-11.52M | $-2.54M | $-218.00K |
| Low Forecast | $-69.07M | $-55.14M | $-53.67M | $-49.39M | $-49.37M | $-41.38M | $-41.49M | $-27.58M | $-38.55M | $-28.34M | $-31.50M | $-25.07M | $-18.85M | $-23.01M | $-23.39M | $-22.79M | $-22.21M | $-16.24M | $-15.76M | $-7.10M | $-13.55M | $-7.36M | $-1.23M | $-13.21M | $-11.52M | $-2.54M | $-218.00K |
| Surprise % | - | - | - | - | - | - | - | - | 0.66% | 0.68% | 0.64% | 0.51% | 0.60% | 0.73% | 0.79% | 0.76% | 0.11% | 1.11% | 0.85% | -1.30% | 7.82% | 0.93% | 13.64% | 1.37% | 0.91% | 9.19% | 156.42% |
4 analysts predict EOLS's average Quarter EBITDA for Jun 21 to be $-15.76M, with a high of $-15.76M and a low of $-15.76M. This is -270.52% lower than Evolus's previous annual EBITDA (Mar 21) of $9.24M.
Evolus Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | $-11.83M | $-16.92M | $-18.14M | $-14.79M | $-13.16M | $-20.28M | $-23.47M | $-17.50M | $-18.18M | $-19.43M | $-15.60M | $6.40M | $-110.69M | $-11.46M | $-21.13M | $-19.73M | $-14.51M | $-26.98M | $-37.57M |
| Avg Forecast | $7.53M | $-627.25K | $-1.88M | $1.25M | $-250.90K | $-7.74M | $-3.29M | $-28.07M | $-7.76M | $-13.96M | $-15.86M | $-25.52M | $-21.64M | $-19.29M | $-16.41M | $-23.20M | $-14.07M | $-17.03M | $-16.31M | $8.84M | $-16.39M | $-25.01M | $-46.97M | $-14.38M | $-49.20M | $-72.68M | $-60.57M |
| High Forecast | $7.53M | $-627.25K | $-1.88M | $1.25M | $-250.90K | $-2.90M | $-3.29M | $-22.46M | $-5.54M | $-13.96M | $-15.86M | $-20.41M | $-17.31M | $-19.29M | $-16.41M | $-18.56M | $-14.07M | $-17.03M | $-16.31M | $10.61M | $-16.39M | $-25.01M | $-46.97M | $-11.51M | $-49.20M | $-72.68M | $-60.57M |
| Low Forecast | $7.53M | $-627.25K | $-1.88M | $1.25M | $-250.90K | $-12.57M | $-3.29M | $-33.68M | $-9.98M | $-13.96M | $-15.86M | $-30.62M | $-25.97M | $-19.29M | $-16.41M | $-27.84M | $-14.07M | $-17.03M | $-16.31M | $7.07M | $-16.39M | $-25.01M | $-46.97M | $-17.26M | $-49.20M | $-72.68M | $-60.57M |
| Surprise % | - | - | - | - | - | - | - | - | 1.52% | 1.21% | 1.14% | 0.58% | 0.61% | 1.05% | 1.43% | 0.75% | 1.29% | 1.14% | 0.96% | 0.72% | 6.76% | 0.46% | 0.45% | 1.37% | 0.29% | 0.37% | 0.62% |
Evolus's average Quarter net income forecast for Jun 21 is $-16.31M, with a range of $-16.31M to $-16.31M. EOLS's average Quarter net income forecast represents a -354.78% decrease compared to the company's last Quarter net income of $6.40M (Mar 21).
Evolus SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | $43.06M | $43.33M | $41.17M | $37.38M | $36.73M | $34.79M | $36.88M | $33.44M | $33.28M | $31.68M | $26.47M | $20.68M | $27.39M | $21.94M | $17.55M | $33.05M | $31.75M | $32.10M | $35.87M |
| Avg Forecast | $170.45M | $136.08M | $132.45M | $121.89M | $121.83M | $99.61M | $102.39M | $53.95M | $94.91M | $69.93M | $77.74M | $63.98M | $69.21M | $56.77M | $57.72M | $47.03M | $54.81M | $40.07M | $38.90M | $17.52M | $33.43M | $18.15M | $3.05M | $24.03M | $28.42M | $6.26M | $537.96K |
| High Forecast | $170.45M | $136.08M | $132.45M | $121.89M | $121.83M | $102.10M | $102.39M | $64.74M | $95.13M | $69.93M | $77.74M | $63.98M | $69.21M | $56.77M | $57.72M | $47.03M | $54.81M | $40.07M | $38.90M | $17.52M | $33.43M | $18.15M | $3.05M | $24.03M | $28.42M | $6.26M | $537.96K |
| Low Forecast | $170.45M | $136.08M | $132.45M | $121.89M | $121.83M | $97.92M | $102.39M | $43.16M | $94.70M | $69.93M | $77.74M | $63.98M | $69.21M | $56.77M | $57.72M | $47.03M | $54.81M | $40.07M | $38.90M | $17.52M | $33.43M | $18.15M | $3.05M | $24.03M | $28.42M | $6.26M | $537.96K |
| Surprise % | - | - | - | - | - | - | - | - | 0.45% | 0.62% | 0.53% | 0.58% | 0.53% | 0.61% | 0.64% | 0.71% | 0.61% | 0.79% | 0.68% | 1.18% | 0.82% | 1.21% | 5.76% | 1.38% | 1.12% | 5.13% | 66.68% |
Evolus's average Quarter SG&A projection for Mar 24 is $53.95M, based on 4 Wall Street analysts, with a range of $43.16M to $64.74M. The forecast indicates a 25.30% rise compared to EOLS last annual SG&A of $43.06M (Dec 23).
Evolus EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | $-0.30 | $-0.00 | $-0.26 | $-0.23 | $-0.36 | $-0.42 | $-0.31 | $-0.33 | $-0.35 | $-0.31 | $0.17 | $-3.28 | $-0.34 | $-0.63 | $-0.59 | $-0.47 | $-0.98 | $-1.37 |
| Avg Forecast | $0.12 | $-0.01 | $-0.03 | $0.02 | $-0.00 | $-0.12 | $-0.05 | $-0.15 | $-0.12 | $-0.22 | $-0.25 | $-0.19 | $-0.17 | $-0.31 | $-0.26 | $-0.34 | $-0.22 | $-0.27 | $-0.26 | $-0.47 | $-0.26 | $-0.40 | $-0.75 | $-0.64 | $-0.78 | $-1.16 | $-0.97 |
| High Forecast | $0.12 | $-0.01 | $-0.03 | $0.02 | $-0.00 | $-0.05 | $-0.05 | $-0.15 | $-0.09 | $-0.22 | $-0.25 | $-0.19 | $-0.17 | $-0.31 | $-0.26 | $-0.34 | $-0.22 | $-0.27 | $-0.26 | $-0.47 | $-0.26 | $-0.40 | $-0.75 | $-0.64 | $-0.78 | $-1.16 | $-0.97 |
| Low Forecast | $0.12 | $-0.01 | $-0.03 | $0.02 | $-0.00 | $-0.20 | $-0.05 | $-0.15 | $-0.16 | $-0.22 | $-0.25 | $-0.19 | $-0.17 | $-0.31 | $-0.26 | $-0.34 | $-0.22 | $-0.27 | $-0.26 | $-0.47 | $-0.26 | $-0.40 | $-0.75 | $-0.64 | $-0.78 | $-1.16 | $-0.97 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 1.35% | 0.00% | 1.40% | 1.37% | 1.17% | 1.61% | 0.91% | 1.47% | 1.29% | 1.19% | -0.37% | 12.56% | 0.85% | 0.84% | 0.92% | 0.60% | 0.85% | 1.42% |
According to 4 Wall Street analysts, Evolus's projected average Quarter EPS for Jun 21 is $-0.26, with a low estimate of $-0.26 and a high estimate of $-0.26. This represents a -252.94% decrease compared to EOLS previous annual EPS of $0.17 (Mar 21).
Evolus Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $1.78 | $10.00 | 461.80% | - |
| PCRX | Pacira BioSciences | $16.45 | $40.00 | 143.16% | Hold |
| EOLS | Evolus | $16.42 | $24.00 | 46.16% | Buy |
| ANIP | ANI Pharmaceuticals | $56.01 | $79.00 | 41.05% | Buy |
| AMPH | Amphastar Pharmaceuticals | $50.59 | $66.00 | 30.46% | Buy |
| ALKS | Alkermes | $26.59 | $34.38 | 29.30% | Hold |
| COLL | Collegium Pharmaceutical | $32.72 | $41.50 | 26.83% | Buy |
| PBH | Prestige Consumer Healthcare | $73.79 | $82.00 | 11.13% | Buy |
| ITCI | Intra-Cellular Therapies | $86.17 | $94.50 | 9.67% | Buy |
| SUPN | Supernus Pharmaceuticals | $34.70 | $38.00 | 9.51% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $22.37 | $18.67 | -16.54% | Buy |
EOLS Forecast FAQ
Is Evolus a good buy?
Yes, according to 4 Wall Street analysts, Evolus (EOLS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of EOLS's total ratings.
What is EOLS's price target?
Evolus (EOLS) average price target is $24 with a range of $20 to $27, implying a 46.16% from its last price of $16.42. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Evolus stock go up soon?
According to Wall Street analysts' prediction for EOLS stock, the company can go up by 46.16% (from the last price of $16.42 to the average price target of $24), up by 64.43% based on the highest stock price target, and up by 21.80% based on the lowest stock price target.
Can Evolus stock reach $20?
EOLS's average twelve months analyst stock price target of $24 supports the claim that Evolus can reach $20 in the near future.
What are Evolus's analysts' financial forecasts?
Evolus's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $262.64M (high $264.21M, low $261.56M), average EBITDA is $-154M (high $-149M, low $-160M), average net income is $-39.349M (high $-28.9M, low $-49.797M), average SG&A $377.78M (high $391.06M, low $365.3M), and average EPS is $-0.332 (high $-0.255, low $-0.409). EOLS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $355.7M (high $355.7M, low $355.7M), average EBITDA is $-227M (high $-227M, low $-227M), average net income is $6.27M (high $6.27M, low $6.27M), average SG&A $560.87M (high $560.87M, low $560.87M), and average EPS is $0.1 (high $0.1, low $0.1).
Did the EOLS's actual financial results beat the analysts' financial forecasts?
Based on Evolus's last annual report (Dec 2023), the company's revenue was $199.72M, beating the average analysts forecast of $194.41M by 2.73%. Apple's EBITDA was $-70.208M, missing the average prediction of $-119M by -41.10%. The company's net income was $-61.685M, missing the average estimation of $-63.096M by -2.24%. Apple's SG&A was $164.94M, missing the average forecast of $306.55M by -46.19%. Lastly, the company's EPS was $-0.0011, missing the average prediction of $-0.785 by -99.86%. In terms of the last quarterly report (Dec 2023), Evolus's revenue was $59.33M, missing the average analysts' forecast of $60.19M by -1.43%. The company's EBITDA was $-25.206M, missing the average prediction of $-38.462M by -34.47%. Evolus's net income was $-11.831M, beating the average estimation of $-7.762M by 52.42%. The company's SG&A was $43.06M, missing the average forecast of $94.91M by -54.63%. Lastly, the company's EPS was $-0.0002, missing the average prediction of $-0.124 by -99.84%